S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

NCT05101070 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

282

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: S-531011
DRUG: Pembrolizumab
DRUG: Bevacizumab

Sponsor

Shionogi

Collaborators

[object Object]